Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 5/20 | 0.49 |
| ▸ | SKP1 | P63208 | 5/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211084 | 0.80 | CKS1B (0.53) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL5214272 | 0.76 | CKS1B (0.49) | CKS1BSKP1SKP2CNR1HCAR3 | |
| SCHEMBL24046599 | 0.73 | CKS1B (0.53) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL12890450 | 0.73 | PDGFRB (0.55) | LMNASMN1; SMN2MAPK10MAPK14NPSR1 | |
| SCHEMBL28700972 | 0.71 | CYP1A2 (0.50) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL19823495 | 0.71 | CKS1B (0.46) | CKS1BSKP1SKP2MAPK14MAPT | |
| SCHEMBL30725768 | 0.71 | CYP1A2 (0.50) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL31498236 | 0.70 | SMN1; SMN2 (0.61) | MEN1KMT2ALMNASMN1; SMN2NPSR1 | |
| SCHEMBL29678556 | 0.70 | ADORA2A (0.64) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL2684042 | 0.70 | CKS1B (0.58) | CKS1BSKP1SKP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216366-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240091223-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2024-03-21 | — | — | US | disclosed |
| WO-2024017964-A1 | INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-4284334-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | Actelion Pharmaceuticals Ltd (CH) | 2023-12-06 | — | — | EP | disclosed |
| CN-116744903-A | Pharmaceutical composition comprising diphenylpyrazine derivatives | 埃科特莱茵药品有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-10544107-B2 | Process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide and novel polymorphs thereof | MAITHRI DRUGS PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | disclosed |
| US-20190152927-A1 | NOVEL PROCESS FOR THE PREPARATION OF 2-{4-[(5,6-DIPHENYL PYRAZIN-2-YL)(ISOPROPYL)AMINO]BUTOXY}-N-(METHYLSULFONYL)ACETAMIDE AND NOVEL POLYMORPHS THEREOF | MAITHRI DRUGS PRIVATE LIMITED (IN) | 2019-05-23 | — | — | US | disclosed |
| WO-2017042828-A2 | PROCESS FOR THE PREPARATION OF SELEXIPAG AND INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042828-A2 | PROCESS FOR THE PREPARATION OF SELEXIPAG AND INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152927-A1 | NOVEL PROCESS FOR THE PREPARATION OF 2-{4-[(5,6-DIPHENYL PYRAZIN-2-YL)(ISOPROPYL)AMINO]BUTOXY}-N-(METHYLSULFONYL)ACETAMIDE AND NOVEL POLYMORPHS THEREOF | PKD1, PKD2, CYP2S1 | CKS1B 234/4885SKP1 60/4885SKP2 313/4885 |
| US-20240091223-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | IL5, CACNA1C, IAPP | CKS1B 4684/4885SKP1 2713/4885SKP2 3081/4885 |
| US-10544107-B2 | Process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide and novel polymorphs thereof | CYP2E1, CYP2S1, CYP1B1 | CKS1B 338/4885SKP1 33/4885SKP2 266/4885 |
| US-20240216366-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | IL5, CACNA1C, IAPP | CKS1B 4684/4885SKP1 2713/4885SKP2 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.